John F. Forbes

TL;DR: There was no convincing heterogeneity in the proportional recurrence reduction with respect to age, nodal status, tumor grade, or progesterone receptor status and no indication of an increase in nonbreast deaths with AIs in either cohort.

TL;DR: Prophylactic use of tamoxifen is contraindicated in women at high risk of thromboembolic disease and the combined evidence indicates that mortality from non-breast-cancer causes is not increased by tamoxIFen.

TL;DR: The amount of prognostic information contained in four widely performed IHC assays is similar to that in the GHI-RS, which confirmed earlier reports that the mRNA-based, 21-gene Genomic Health recurrence score provided additional prognosis information regarding distant recurrence beyond that obtained from classical clinicopathologic factors.

TL;DR: This study confirmed the performance of RS in postmenopausal HR+ patients treated with tamoxifen in a large contemporary population and demonstrated that RS is an independent predictor of DR in N0 and N+ hormone receptor-positive patientstreated with anastrozole, adding value to estimates with standard clinicopathologic features.

TL;DR: Tumours downsized by NACT might have higher local recurrence after breast-conserving therapy than might tumours of the same dimensions in women who have not received NACT.